| Cat. No. |
Product Name |
Information |
| PC-Ab1113 |
Moxetumomab
|
Moxetumomab pasudotox is an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. Moxetumomab binds to CD22 on HCL cells and leads to apoptotic cell death after internalization and trafficking of the toxin to the cytosol. CD22 is a single chain integral membrane molecule and a member of the immunoglobulin gene superfamily, an inhibitory B lymphocyte receptor specifically recognizing α2,6 sialic acids. It functions as an adhesion receptor and a signaling molec |
| PC-Ab1112 |
Polatuzumab
|
Polatuzumab (Anti-human CD79b) is a human CD79b mAb, component of antibody-drug conjugate (ADC) Polatuzumab vedotin. Polatuzumab is internalized, cleaved by lysosomal proteases, thereby delivering MMAE to malignant B-cells. The released MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis. CD79B is a subunit of the heterodimer B-cell receptor Igα/Igβ (CD79A/CD79B), also known as B29, Ig beta and B cell antigen receptor complex-associated protein |
| PC-Ab1111 |
KWAR23
|
KWAR23 is a monoclonal anti-human SIRPα antibody that binds to human SIRPα with high affinity, blocks the interaction of CD47 on one cell with SIRPα on a phagocytic cell. KWAR23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines, restores chemokine secretion in human macrophages in vitro, greatly augments myeloid cell-dependent killing of a collec-tion of hematopoietic and nonhematopoietic human tumor-derived cell lines.. |
| PC-Ab1110 |
Ofatumumab
|
Ofatumumab (GSK-1841157, OMB157) is a fully humanized, high-affinity monoclonal antibody whose epitope on CD20 is distinct from rituximab’s target. Ofatumumab induces efficient complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, even when CD20 expression is low. Ofatumumab inhibits early-stage B lymphocyte activation.. |
| PC-Ab1109 |
Guselkumab
|
Guselkumab (CNTO-1959) is a fully human immunoglobulin-G1-lambda (IgG1λ) monoclonal antibody, selectively binds to the p19 subunit of IL-23 in dendritic cells and keratinocytes and blocks its interaction with the IL-23 receptor, which further prevents the release of other pro-inflammatory cytokines and chemokines via stimulation of immune cells, such as T helper 17 (Th17) cells. Guselkumab serum levels of IL-17A, IL-17F, and IL-22, inhibits the release of proinflammatory cytokines and chemokines |
| PC-Ab1108 |
Sabatolimab
|
Binds and blocks the interaction TIM3/PtdSer (Kd=0.16 nM, PtdSer Blocking IC50=6.4 nM) , restore effector T cell activity to promote antitumor immunity by altering myeloid cells in tumor microenvironment. TIM-3 may synergize with PD-1 blockade by enhancing or altering the innate immune response and may form part of a resistance mechanism to PD-1 blockade.. |
| PC-Ab1107 |
TSR-033
|
TSR-033 is a high affinity humanized IgG4, κ mAb that specifically binds LAG-3 and blocks the interaction between LAG-3 and its ligand MHC Class II. TSR-033 serves as a functional antagonist, enhancing in vitro T-cell activation both in mixed lymphocyte reactions and staphylococcal enterotoxin B-driven stimulation assays. In a humanized mouse non-small cell lung carcinoma model, TSR-033 boosted the antitumor efficacy of PD-1 monotherapy, with a concomitant increase in immune activation.. |
| PC-Ab1106 |
Rovalpituzumab
|
Rovalpituzumab is the antibody part of Rovalpituzumab tesirine (Rova-T). Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) and was initially developed for small cell lung cancer.. |
| PC-Ab1105 |
Oleclumab
|
Oleclumab (MEDI 9447) is a human IgG1 lambda mAb with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. |
| PC-Ab1104 |
Sintilimab
|
Sintilimab (IBI 308) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. . |
| PC-Ab1103 |
Toripalimab
|
Toripalimab (JS 001, SO-001, TAB-001) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function. Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells.. |
| PC-Ab1102 |
Leramilimab
|
LAG525 (Leramilimab) is a high-affinity, ligand-blocking monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth. LAG525 blocks binding of LAG-3, a negative regulator of T-cell signalling, to MHC class II on tumour cells, which renders the tumour microenvironment less immunosuppressive, and may therefore enhance the activity of PD-1 blockade.. |
